Enzyvant Logo White Verticle

Patient Focused. Results Driven.



Transformative therapies for rare diseases with high unmet needs.


Innovative partnerships that create new opportunities in the rare disease field.


On our commitment to the patients, families, and communities we serve.



Pediatric congenital athymia

Children with congenital athymia are generally born without a thymus, resulting in severe immunodeficiency due to the inability to produce normally functioning T cells, which defend against infection and regulate essential processes in the immune system. Left untreated, congenital athymia is fatal, typically within the first 24 months of life.


Acid ceramidase deficiency manifesting as Farber disease

Acid ceramidase deficiency is a devastating lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

December 30, 2019

Effective December 27, 2019, DSP has acquired from Roivant 100% of “Sumitovant Biopharma,” a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Enzyvant, that comprise Sumitovant.

November 1, 2019

Under a definitive agreement signed yesterday, DSP will acquire Roivant’s ownership interest in Enzyvant and four other Roivant companies with promising pipelines.

October 16, 2019

Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare, life-threatening conditions, today announced the appointment of Jeb Ledell as Chief Operating Officer.

Contact us for more information.